SUMMARY
- Network Bio raised $50M in funding.
- The funding will support platform and AI model development.
- Network Bio uses AI to advance biomedical research.
Follow us
Follow usNetwork Bio, a Boston, MA-based biotechnology company building disease-specific AI models from human biological data, has raised $50 million in a financing round.
The round saw backers Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund, JSL Health Capital, and other life science and AI funds.
The company will use the capital to expand its life sciences platform and advance AI models trained on large-scale biological and clinical datasets.
Funding Snapshot
| Metric | Details |
|---|---|
| Fundraise Amount | $50 Million |
| Funding Type | Financing Round |
| Investors | Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund, JSL Health Capital, Others |
| Company | Network Bio |
| Sector | Biotechnology / AI |
| Headquarters | Boston, Massachusetts, US |
RECOMMENDED FOR YOU
About Network Bio
Founded in 2022 by Asad Ali Ahmad, Raphael Potter, and Hani Goodarzi, Network Bio develops AI models designed to learn disease biology from human biological and clinical data.
The company's platform combines biological datasets from academic medical centers with AI architectures built specifically for multimodal biological information. Its goal is to identify biological patterns that can transfer across diseases, tissues, and different types of data.
Read More:California-Based RockRose Risk Raises $12.5M in Series A Funding
Network Bio has established collaborations with US academic medical centers and has connected datasets covering areas such as immunology, metabolic disease, cardiovascular disease, and autoimmune conditions.
Core offerings include:
- Disease-specific AI models
- Human biological data atlases
- Multimodal biological data analysis
- Clinical and molecular data integration
- AI infrastructure for biomedical research
Core Technologies / Products / Services
| Capability/Product | Application/Use Case |
| Biological Research Network | Sources and connects tissue, blood, and clinical data |
| Disease-Specific AI Models | Identifies patterns associated with specific diseases |
| Multimodal Data Platform | Integrates molecular, clinical, and biological datasets |
| Bio-Native AI Architecture | Learns from complex biological data |
Leadership Comments
"Every patient leaves a barcode of their disease in their tissue, and until now no one has been able to read those barcodes at scale," said Asad Ali Ahmad, Ph.D., CEO and Co-Founder, Network Bio. "Working with the biobanks of some of the country's leading academic medical centers, we built the network that makes reading them possible.
“No single academic medical center can capture the full complexity of human disease," said Kimberly Muller, Chief Innovation Officer, CU Anschutz Innovations. "By bringing together biobanks from leading institutions with industry partners, Network Bio is creating a research resource that reflects diverse patient populations and supports discoveries that can translate into real-world clinical practice."
Read More:Data Analytics-Based Ours Privacy Raises $15M in Series A Funding
Recommended Stories for You
Devin Jacobs Mar 14, 2026
Devin Jacobs Apr 20, 2026
Devin Jacobs Feb 14, 2024
Devin Jacobs Apr 14, 2026
Devin Jacobs Aug 7, 2026
Trending Stories
[Funding News] Protect AI Raises $60 Million in Series B Funding Round
Auxilium Health Lands $3.4M to Advance Biomaterial Platform Toward FDA Clearance
Immunocine Cancer Center Appoints Vita S. Salsman as Executive Director
Shannon Wu Co-Founded OpenHome Announces Partnership With ElevenLabs
Russ Tedrake Co-founded Walden Robotics Secures $300M to Build AI-Powered Robots
Silicon Data Raises $30.5 Million Series A to Build AI Compute Benchmark Layer
CVR Energy and CVR Partners Announce Leadership Changes
Riskified Announces the Appointment of Ronen Assia to its Board of Directors
